Table of Contents

company-logo

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Genetic Technologies Dividend Announcement

• Genetic Technologies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Genetic Technologies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Genetic Technologies Dividend History

Genetic Technologies Dividend Yield

Genetic Technologies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Genetic Technologies stock? Use our calculator to estimate your expected dividend yield:

Genetic Technologies Financial Ratios

P/E ratio-11.38
PEG ratio-0.67
P/B ratio94.67
ROE-458.46%
Payout ratio0.00%
Current ratio0.88
Quick ratio0.83
Cash Ratio0.24

Genetic Technologies Dividend FAQ

Does Genetic Technologies stock pay dividends?
Genetic Technologies does not currently pay dividends to its shareholders.
Has Genetic Technologies ever paid a dividend?
No, Genetic Technologies has no a history of paying dividends to its shareholders. Genetic Technologies is not known for its dividend payments.
Why doesn't Genetic Technologies pay dividends?
There are several potential reasons why Genetic Technologies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Genetic Technologies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Genetic Technologies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Genetic Technologies a dividend aristocrat?
Genetic Technologies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Genetic Technologies a dividend king?
Genetic Technologies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Genetic Technologies a dividend stock?
No, Genetic Technologies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Genetic Technologies stocks?
To buy Genetic Technologies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Genetic Technologies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.